Comparative Pharmacology
Head-to-head clinical analysis: DEMADEX versus LASIX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMADEX versus LASIX.
DEMADEX vs LASIX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits the Na-K-2Cl symporter in the thick ascending limb of the loop of Henle, reducing reabsorption of sodium, chloride, and potassium, leading to increased urine output.
Furosemide inhibits the Na-K-2Cl cotransporter in the thick ascending limb of the loop of Henle, reducing sodium, chloride, and water reabsorption and increasing urinary output.
Oral: 5-10 mg once daily; may increase to 20 mg once daily if needed. IV: 5-10 mg once daily; may increase to 20 mg once daily if needed. Maximum dose: 40 mg/day.
20-80 mg IV or PO once or twice daily; maximum 600 mg/day IV or PO.
None Documented
None Documented
The terminal elimination half-life is approximately 4 hours (range 2-8 hours) in patients with normal renal function. In renal impairment (creatinine clearance <30 mL/min), half-life is prolonged to 10-12 hours due to reduced renal clearance. In hepatic cirrhosis, half-life may be extended to 8-9 hours due to decreased metabolism.
Terminal elimination half-life is approximately 1.5-2 hours. In renal impairment (CrCl <20 mL/min), half-life may prolong to up to 2-4 hours; in end-stage renal disease or heart failure, may exceed 4 hours.
Approximately 50% of the absorbed dose is excreted unchanged in the urine via glomerular filtration and active tubular secretion. The remainder undergoes hepatic metabolism to glucuronide conjugates and minor oxidative metabolites, with biliary excretion of metabolites (about 30-40% of the dose) eliminated in feces. Renal clearance is the primary route for the parent drug.
Primarily renal excretion (50-80% as unchanged drug) via glomerular filtration and proximal tubular secretion; minor fecal elimination (<5%).
Category C
Category C
Loop Diuretic
Loop Diuretic